Literature DB >> 20089962

Long-term recovery after hematopoietic cell transplantation: predictors of quality-of-life concerns.

F Lennie Wong1, Liton Francisco, Kayo Togawa, Alysia Bosworth, Mitzi Gonzales, Cara Hanby, Melanie Sabado, Marcia Grant, Stephen J Forman, Smita Bhatia.   

Abstract

This prospective longitudinal study examined the quality of life (QOL) after hematopoietic cell transplantation (HCT) and identified risk factors of poor QOL in 312 adult autologous and allogeneic HCT patients. Physical, psychological, social, and spiritual well-being was assessed before HCT, 6 months, and 1, 2, and 3 years after HCT. For all HCT patients, physical QOL was stable from before to after HCT (P > .05); psychologic (P < .001), social (P < .001), and spiritual (P = .03) QOL improved at 6 months. Study noncompleters (because of illness or death) had worse QOL. Allogeneic patients reported worse physical and psychologic well-being (P < .05). Older patients reported worse physical but better social well-being regardless of HCT type (P < .05). Two or more domains were affected by race/ethnicity, household income, and education in autologous patients, and by body mass index (BMI), decline in BMI, primary diagnosis, and chronic graft-versus-host disease (GVHD) in allogeneic patients (P < .05). At 3 years, 74% of HCT patients were employed full or part time. Older autologous patients with lower pre-HCT income were less likely to work (P < .05); allogeneic patients with chronic GVHD were less likely to work (P = .002). Multidisciplinary efforts to identify and support vulnerable subgroups after HCT need to be developed.

Entities:  

Mesh:

Year:  2010        PMID: 20089962      PMCID: PMC2845903          DOI: 10.1182/blood-2009-06-225631

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  50 in total

1.  The concept of clinically meaningful difference in health-related quality-of-life research. How meaningful is it?

Authors:  R D Hays; J M Woolley
Journal:  Pharmacoeconomics       Date:  2000-11       Impact factor: 4.981

2.  Psychological functioning and quality of life following bone marrow transplantation: a 3-year follow-up study.

Authors:  S Broers; A A Kaptein; S Le Cessie; W Fibbe; M W Hengeveld
Journal:  J Psychosom Res       Date:  2000-01       Impact factor: 3.006

3.  Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.

Authors:  N E Bush; G W Donaldson; M H Haberman; R Dacanay; K M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2000       Impact factor: 5.742

4.  Quality of life and social integration after allogeneic hematopoietic SCT.

Authors:  S Bieri; E Roosnek; C Helg; F Verholen; D Robert; B Chapuis; J Passweg; R Miralbell; Y Chalandon
Journal:  Bone Marrow Transplant       Date:  2008-08-18       Impact factor: 5.483

5.  Late congestive heart failure after hematopoietic cell transplantation.

Authors:  Saro H Armenian; Can-Lan Sun; Liton Francisco; Julia Steinberger; Seira Kurian; F Lennie Wong; Jon Sharp; Richard Sposto; Stephen J Forman; Smita Bhatia
Journal:  J Clin Oncol       Date:  2008-09-22       Impact factor: 44.544

6.  Quality of life in 244 recipients of allogeneic bone marrow transplantation.

Authors:  S Chiodi; S Spinelli; G Ravera; A R Petti; M T Van Lint; T Lamparelli; F Gualandi; D Occhini; N Mordini; G Berisso; S Bregante; F Frassoni; A Bacigalupo
Journal:  Br J Haematol       Date:  2000-09       Impact factor: 6.998

7.  Cardiac and pulmonary toxicity in patients undergoing high-dose chemotherapy for lymphoma and breast cancer: prognostic factors.

Authors:  B E Brockstein; C Smiley; J Al-Sadir; S F Williams
Journal:  Bone Marrow Transplant       Date:  2000-04       Impact factor: 5.483

8.  Recovery after stem-cell transplantation for hematologic diseases.

Authors:  S J Lee; D Fairclough; S K Parsons; R J Soiffer; D C Fisher; R L Schlossman; J H Antin; J C Weeks
Journal:  J Clin Oncol       Date:  2001-01-01       Impact factor: 44.544

9.  Validation of self-reported complications by bone marrow transplantation survivors.

Authors:  A D Louie; L L Robison; M Bogue; S Hyde; S J Forman; S Bhatia
Journal:  Bone Marrow Transplant       Date:  2000-06       Impact factor: 5.483

Review 10.  Quality of life after allogeneic hematopoietic cell transplantation.

Authors:  Joseph Pidala; Claudio Anasetti; Heather Jim
Journal:  Blood       Date:  2009-03-31       Impact factor: 22.113

View more
  47 in total

1.  Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics.

Authors:  Marcia Grant; Liz Cooke; Anna Cathy Williams; Smita Bhatia; Leslie Popplewell; Gwen Uman; Stephen Forman
Journal:  Support Care Cancer       Date:  2012-02-09       Impact factor: 3.603

2.  Quality of life and outcomes in patients⩾60 years of age after allogeneic hematopoietic cell transplantation.

Authors:  B K Hamilton; L Rybicki; J Dabney; L McLellan; H Haddad; L Foster; D Abounader; M Kalaycio; R Sobecks; R Dean; H Duong; B T Hill; B J Bolwell; E A Copelan
Journal:  Bone Marrow Transplant       Date:  2014-07-28       Impact factor: 5.483

3.  Adverse psychological outcomes in long-term survivors of hematopoietic cell transplantation: a report from the Bone Marrow Transplant Survivor Study (BMTSS).

Authors:  Can-Lan Sun; Liton Francisco; K Scott Baker; Daniel J Weisdorf; Stephen J Forman; Smita Bhatia
Journal:  Blood       Date:  2011-08-05       Impact factor: 22.113

Review 4.  Reduced-intensity conditioned allogeneic SCT in adults with AML.

Authors:  R Reshef; D L Porter
Journal:  Bone Marrow Transplant       Date:  2015-03-02       Impact factor: 5.483

5.  Circadian Rhythmicity as a Predictor of Quality of Life in Allogeneic Hematopoietic Cell Transplant Patients.

Authors:  Aasha I Hoogland; Hailey W Bulls; Brian D Gonzalez; Brent J Small; Lianqi Liu; Joseph Pidala; Heather S L Jim; Asmita Mishra
Journal:  J Pain Symptom Manage       Date:  2019-01-31       Impact factor: 3.612

6.  Ongoing graft-versus-host disease is a risk factor for azoospermia after allogeneic hematopoietic stem cell transplantation: a survey of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Alicia Rovó; Mahmoud Aljurf; Sandra Chiodi; Simonetta Spinelli; Nina Salooja; Gülsan Sucak; Ann Hunter; Tan Swee Kim; Gérard Socié; Maria Teresa van Lint; Jakob R Passweg; Mutlu Arat; Manuela Badoglio; André Tichelli
Journal:  Haematologica       Date:  2012-08-28       Impact factor: 9.941

7.  Similar survival, but better quality of life after myeloablative transplantation using unrelated cord blood vs matched sibling donors in adults with hematologic malignancies.

Authors:  H-L Liu; Z-M Sun; L-Q Geng; X-B Wang; K-Y Ding; J Tong; B-L Tang; C-Y Zhou; W Yao; C-C Zheng; K-D Song; X-Y Zhu; W Wei; Y Wang
Journal:  Bone Marrow Transplant       Date:  2014-05-19       Impact factor: 5.483

8.  Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.

Authors:  Areej El-Jawahri; Joseph Pidala; Yoshi Inamoto; Xiaoyu Chai; Nandita Khera; William A Wood; Corey Cutler; Mukta Arora; Paul A Carpenter; Jeanne Palmer; Mary Flowers; Daniel Weisdorf; Steven Pavletic; Samantha Jaglowski; Madan Jagasia; Stephanie J Lee; Yi-Bin Chen
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-09       Impact factor: 5.742

Review 9.  The Role of Spirituality in Patients Undergoing Hematopoietic Stem Cell Transplantation: a Systematic Mixed Studies Review.

Authors:  Li-Yuan Zheng; Hua Yuan; Zi-Jun Zhou; Bao-Xing Guan; Ping Zhang; Xiu-Ying Zhang
Journal:  J Gen Intern Med       Date:  2020-02-24       Impact factor: 5.128

10.  Late effects and healthcare needs of survivors of allogeneic stem cell transplantation: a qualitative study.

Authors:  Jessica P Hwang; Aimee K Roundtree; Sergio A Giralt; Maria Suarez-Almazor
Journal:  BMJ Support Palliat Care       Date:  2012-08-03       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.